<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">2168-622X</issn><issn pub-type="epub">2168-6238</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11923773</article-id><article-id pub-id-type="pmcid-ver">PMC11923773.1</article-id><article-id pub-id-type="pmcaid">11923773</article-id><article-id pub-id-type="pmcaiid">11923773</article-id><article-id pub-id-type="pmid">40105821</article-id><article-id pub-id-type="doi">10.1001/jamapsychiatry.2025.0054</article-id><article-id pub-id-type="publisher-id">yoi250004</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years</article-title><alt-title alt-title-type="headline">Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years</alt-title><alt-title alt-title-type="running-head">Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="B">Beth</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><degrees>MPH</degrees><xref rid="yoi250004aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="CM">Christopher M.</given-names></name><degrees>PharmD</degrees><degrees>DrPH</degrees><degrees>MPH</degrees><xref rid="yoi250004aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Volkow</surname><given-names initials="ND">Nora D.</given-names></name><degrees>MD</degrees><xref rid="yoi250004aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rikard</surname><given-names initials="SM">S. Michaela</given-names></name><degrees>PhD</degrees><xref rid="yoi250004aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dowell</surname><given-names initials="D">Deborah</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="yoi250004aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Einstein</surname><given-names initials="EB">Emily B.</given-names></name><degrees>PhD</degrees><xref rid="yoi250004aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guy</surname><given-names initials="GP">Gery P.</given-names></name><degrees>PhD</degrees><degrees>MPH</degrees><xref rid="yoi250004aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tomoyasu</surname><given-names initials="N">Naomi</given-names></name><degrees>PhD</degrees><xref rid="yoi250004aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ko</surname><given-names initials="J">Jean</given-names></name><degrees>PhD</degrees><xref rid="yoi250004aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baldwin</surname><given-names initials="G">Grant</given-names></name><degrees>PhD</degrees><xref rid="yoi250004aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olsen</surname><given-names initials="Y">Yngvild</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="yoi250004aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Compton</surname><given-names initials="WM">Wilson M.</given-names></name><degrees>MD</degrees><degrees>MPE</degrees><xref rid="yoi250004aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="yoi250004aff1"><label>1</label>National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland</aff><aff id="yoi250004aff2"><label>2</label>Substance Abuse and Mental Health Services Administration, Rockville, Maryland</aff><aff id="yoi250004aff3"><label>3</label>Centers for Disease Control and Prevention, Atlanta, Georgia</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> December 23, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> March 19, 2025. doi:<uri content-type="doi">10.1001/jamapsychiatry.2025.0054</uri></p><corresp id="yoi250004cor1"><bold>Corresponding Author:</bold> Wilson M. Compton, MD, MPE, National Institute on Drug Abuse, National Institutes of Health, 3WFN Room 09D18, MSC 6025, 301 N Stonestreet Ave, Bethesda, MD 20892 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="wcompton@nida.nih.gov">wcompton@nida.nih.gov</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Han and Rikard had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Han, Jones, Volkow, Einstein, Tomoyasu, Baldwin, Compton.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Han, Volkow, Rikard, Dowell, Guy, Ko, Baldwin, Olsen, Compton.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Han, Volkow, Baldwin, Compton.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> Han, Volkow, Rikard, Ko.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Jones, Volkow, Ko, Olsen, Compton.</p><p><italic toggle="yes">Supervision:</italic> Jones, Volkow, Einstein, Tomoyasu, Compton.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Compton reported long-term stock holdings in General Electric Co, 3M Companies, and Pfizer Inc outside the submitted work. No other disclosures were reported.</p><p><bold>Funding/Support:</bold> This study was sponsored by the <funding-source rid="sp1">National Institute on Drug Abuse</funding-source> of the <funding-source rid="sp2">National Institutes of Health</funding-source>, the <funding-source rid="sp3">Substance Abuse and Mental Health Services Administration</funding-source>, and the <funding-source rid="sp4">Centers for Disease Control and Prevention</funding-source>.</p><p><bold>Role of the Funder/Sponsor:</bold> The sponsors supported the authors, who were responsible for preparation, review, and approval of the manuscript and the decision to submit the manuscript for publication. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The sponsors reviewed and approved the manuscript.</p><p><bold>Disclaimer:</bold> The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse of the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, the Centers for Disease Control and Prevention, and the US Department of Health and Human Services.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-YOI250004-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-03-19T10:00"><day>19</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>82</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">484783</issue-id><fpage>572</fpage><lpage>581</lpage><history><date date-type="received"><day>26</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>03</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-07 01:25:33.100"><day>07</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamapsychiatry-e250054.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamapsychiatry-e250054.pdf">jamapsychiatry-e250054.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archpsyc/fullarticle/10.1001/jamapsychiatry.2025.0054"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-yoi250004-1"><title>Question</title><p>As stimulants are increasingly prescribed, what is the prevalence of prescription stimulant use, prescription stimulant misuse, and prescription stimulant use disorder (PSUD) among adults aged 18 to 64 years in the US?</p></sec><sec id="ab-yoi250004-2"><title>Findings</title><p>Among 18- to 64-year-old US adults using prescription stimulants, 25.3% reported misuse, and 9.0% had PSUD. Among those with PSUD, 72.9% solely used their own prescribed stimulants, 87.1% used amphetamines, 42.5% reported no misuse, and 63.6% had mild PSUD. The prevalence of misuse was 3.1 times higher and the prevalence of PSUD was 2.2 times higher among those using prescription amphetamines than among those using methylphenidate.</p></sec><sec id="ab-yoi250004-3"><title>Meaning</title><p>Regardless of prescription stimulant misuse status, screening for and treating PSUD are needed for US adults aged 18 to 64 years using prescription stimulants, especially those receiving prescription amphetamines.</p></sec></abstract><abstract><sec id="ab-yoi250004-4"><title>Importance</title><p>Stimulants are increasingly prescribed for US adults. Whether such prescribing is associated with misuse and prescription stimulant use disorder (PSUD) is less understood.</p></sec><sec id="ab-yoi250004-5"><title>Objectives</title><p>To examine (1) sex- and age-specific trends in the number of persons dispensed stimulants and trends in dispensed prescription stimulants by prescriber specialty in 2019 through 2022; (2) prevalence of misuse and PSUD by use of prescription amphetamine-type stimulants (hereafter referred to as <italic toggle="yes">amphetamines</italic>) and methylphenidate; and (3) PSUD prevalence and sociodemographic and behavioral health correlates among persons using prescription stimulants with and without prescription stimulant misuse.</p></sec><sec id="ab-yoi250004-6"><title>Design, Setting, and Participants</title><p>This cross-sectional survey study used the 2019-2022 IQVIA Total Patient Tracker and National Prescription Audit New to Brand databases and the 2021-2022 National Surveys on Drug Use and Health (NSDUH) (community-dwelling 18- to 64-year-old individuals). Data analysis was performed from March to April 2024.</p></sec><sec id="ab-yoi250004-7"><title>Exposure</title><p>Past-year use of prescription stimulants.</p></sec><sec id="ab-yoi250004-8"><title>Main Outcomes and Measures</title><p>PSUD using <italic toggle="yes">DSM-5</italic> criteria.</p></sec><sec id="ab-yoi250004-9"><title>Results</title><p>Of the sampled 83&#8201;762 adults aged 18 to 64 years, 33.8% (unweighted) were aged 18 to 25 years, 53.0% (unweighted) were aged 26 to 49 years, and 56.0% (unweighted) were women. Among those using prescription stimulants, 25.3% (95% CI, 23.8%-26.8%) reported misuse, and 9.0% (95% CI, 8.0%-10.0%) had PSUD. Among those with PSUD, 72.9% (95% CI, 68.3%-77.6%) solely used their own prescribed stimulants, 87.1% (95% CI, 82.3%-90.8%) used amphetamines, 42.5% (95% CI, 36.6%-48.5%) reported no misuse, and 63.6% (95% CI, 56.8%-69.8%) had mild PSUD. Individuals using amphetamines, compared with those using methylphenidate, had higher prevalence ratios of misuse (3.1 [95% CI, 2.2-4.3]) and PSUD (2.2 [95% CI, 1.3-3.8]). The largest increase in the number of individuals dispensed prescription stimulants was among women aged 35 to 64 years, from 1.2 million in quarter 1 of 2019 to 1.7 million in quarter 4 of 2022 (average quarterly percentage change, 2.6% [95% CI, 2.1%-3.1%]). The prevalence of prescription stimulant misuse was lower among women aged 35 to 64 years using these medications (13.7% [95% CI, 11.1%-16.8%]) than other sex- and age-specific subgroups (ranging from 22.0% [95% CI, 17.9%-26.7%] for men aged 35-64 years to 36.8% [95% CI, 32.6%-41.2%] for women aged 18-25 years).</p></sec><sec id="ab-yoi250004-10"><title>Conclusions and Relevance</title><p>High prevalence of prescription stimulant misuse and PSUD (regardless of misuse status) suggests the importance of ensuring clinically appropriate use and of screening for and treating PSUD among all adults prescribed stimulants, especially those using amphetamines. Findings may suggest potential progress in addressing the mental health care gap for middle-aged women and the need for evidence-based clinical guidance and training on benefits and risks of prescription stimulants for adults.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cross-sectional survey study examines the prevalence of prescription stimulant use, misuse, and use disorder among US adults aged 18 to 64 years.</p></abstract><funding-group><award-group><funding-source id="sp1">National Institute on Drug Abuse</funding-source></award-group></funding-group><funding-group><award-group><funding-source id="sp2">National Institutes of Health</funding-source></award-group></funding-group><funding-group><award-group><funding-source id="sp3">Substance Abuse and Mental Health Services Administration</funding-source></award-group></funding-group><funding-group><award-group><funding-source id="sp4">Centers for Disease Control and Prevention</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>